193 related articles for article (PubMed ID: 9064908)
1. [Current trends in the biological therapy of malignant tumors].
Khanson KP; Afanas'ev BV; Bershteĭn LM; Blinov NN; Gershanovich ML; Imianitov EN; Moiseenko VM; Okulov VB; Togo AV
Vopr Onkol; 1996; 42(5):7-12. PubMed ID: 9064908
[No Abstract] [Full Text] [Related]
2. Prospects for tumour therapy using gene transfer.
Collins MK; Patel P; Flemming CL; Eccles SA
Bone Marrow Transplant; 1992; 9 Suppl 1():171-3. PubMed ID: 1504662
[No Abstract] [Full Text] [Related]
3. Immunotherapeutic strategies for neoplasia.
Talmadge JE
Dev Biol Stand; 1992; 77():17-28. PubMed ID: 1426659
[No Abstract] [Full Text] [Related]
4. IL-2 gene transduction in malignant cells: applications in cancer containment.
Roth C; Mir L; Cressent M; Quintin-Colonna F; Ley V; Fradelizi D; Kourilsky P
Bone Marrow Transplant; 1992; 9 Suppl 1():174-5. PubMed ID: 1504663
[No Abstract] [Full Text] [Related]
5. Cancer vaccines in gene therapy.
Blankenstein T; Qin Z
Gene Ther; 1996 Feb; 3(2):95-6. PubMed ID: 8867856
[No Abstract] [Full Text] [Related]
6. [Current issues in immunotherapy of tumors in the context of macrophage reaction to tissue damage fixed through evolution].
Okulov VB
Vopr Onkol; 1997; 43(1):102-6. PubMed ID: 9133074
[No Abstract] [Full Text] [Related]
7. Molecular approaches to cancer immunotherapy.
Forni G; Cavallo F; Consalvo M; Allione A; Dellabona P; Casorati G; Giovarelli M
Cytokines Mol Ther; 1995 Dec; 1(4):225-48. PubMed ID: 9384678
[TBL] [Abstract][Full Text] [Related]
8. Biological response modifiers.
Clark JW
Cancer Chemother Biol Response Modif; 1996; 16():239-73. PubMed ID: 8639384
[No Abstract] [Full Text] [Related]
9. Biological response modifiers.
Clark JW
Cancer Chemother Biol Response Modif; 1993; 14():207-26. PubMed ID: 8312103
[No Abstract] [Full Text] [Related]
10. Immunotherapy-based treatment strategies for malignant mesothelioma.
Schwarzenberger P; Byrne P; Kolls JK
Curr Opin Mol Ther; 1999 Feb; 1(1):104-11. PubMed ID: 11249674
[TBL] [Abstract][Full Text] [Related]
11. [Thymus hormones in the immunotherapy of malignant neoplasms (a review of the literature)].
Nikol'skiĭ IS
Vrach Delo; 1988 Aug; (8):77-82. PubMed ID: 3061171
[No Abstract] [Full Text] [Related]
12. Biological response modifiers: preclinical and clinical results.
Talmadge JE; Clark J
Cancer Chemother Biol Response Modif; 1987; 9():454-72. PubMed ID: 3079413
[No Abstract] [Full Text] [Related]
13. [Current data on immunotherapy].
Tigaud JM; Duarte A; Psyche S; Droz JP
Rev Infirm; 1991 Dec; 41(19):30-1. PubMed ID: 1771342
[No Abstract] [Full Text] [Related]
14. Targeting gene therapy--a reality?
Dranoff G
Mol Ther; 2000 Feb; 1(2):117-8. PubMed ID: 10933921
[No Abstract] [Full Text] [Related]
15. What's new in surgical oncology: impact of immunology and tumour biology.
Heys SD; Eremin O
J R Coll Surg Edinb; 1990 Dec; 35(6):341-4. PubMed ID: 2086793
[No Abstract] [Full Text] [Related]
16. Natural killer cell-based immunotherapy in cancer: current insights and future prospects.
Sutlu T; Alici E
J Intern Med; 2009 Aug; 266(2):154-81. PubMed ID: 19614820
[TBL] [Abstract][Full Text] [Related]
17. Locoregional treatment of malignant hepatic tumors with biologic response modifiers.
Yamamoto A; Sato T
Surg Oncol Clin N Am; 2008 Oct; 17(4):935-55, xii. PubMed ID: 18722927
[TBL] [Abstract][Full Text] [Related]
18. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
[TBL] [Abstract][Full Text] [Related]
19. Application of cell engineering technology to the tumour immunotherapeutic drug: a review.
Chen ZN; Xing JL; Bian HJ; Mi L; Jiang JL
Cell Biol Int; 2001; 25(10):1013-5. PubMed ID: 11589619
[TBL] [Abstract][Full Text] [Related]
20. Biological therapy in cancer.
Idowu OE
Niger J Med; 2001; 10(3):102-5. PubMed ID: 11806006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
